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positive cells was present in the normal peritoneum, which 
were SMA negative on consecutive sections. In patients on PD, 
a high number of PDGFRβ were also positive for SMA. In EPS, 
the majority of podoplanin-positive cells were positive for 
PDGFRβ. In peritoneal biopsies from normal and uremic pa-
tients, the expression of SMA was mainly restricted to cells of 
arterial walls. Podoplanin expression was restricted to lym-
phatic vessels in normal peritoneum, in uremic patients, and in 
patients on PD without EPS.  Conclusions: As podoplanin-pos-
itive myofibroblasts express PDGFRβ, these cells might be re-
lated to pericytes (rather than other sources of fibroblasts). 
PDGFRβ might turn out to be a therapeutic target in EPS. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Simple peritoneal fibrosis and encapsulating perito-
neal sclerosis (EPS) are important consequences of 
long-term peritoneal dialysis (PD) with major impact 
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 Abstract 
 Introduction: Simple peritoneal fibrosis and encapsulating 
peritoneal sclerosis (EPS) are important lesions in the perito-
neum of patients on peritoneal dialysis (PD). We have previ-
ously described a population of podoplanin-positive myofi-
broblasts in peritoneal biopsies from patients with EPS. Plate-
let-derived growth factor receptor-β (PDGFRβ) is a marker of 
pericytes, and PDGFs might be involved in the fibrotic response 
of the peritoneum. This study aimed to describe PDGFRβ in the 
human peritoneum.  Methods: In this retrospective analysis, we 
localized PDGFRβ in peritoneal biopsies from patients with EPS 
(n = 6) and patients on PD without signs of EPS (n = 5), and 
compared them with normal peritoneum (n = 4) and perito-
neum from uremic patients (n = 5). Consecutive sections were 
stained for smooth-muscle actin (SMA) and podoplanin. Slides 
were scored semiquantitatively by 2 observers blinded to the 
diagnosis.  Results: PDGFRβ was expressed by cells of arterial 
walls in all biopsies. A prominent population of PDGFRβ-
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on technical and patient survival  [1, 2] . We have previ-
ously described a population of podoplanin-positive 
cells in peritoneal biopsies from patients with EPS  [3, 4] . 
These cells coexpress smooth-muscle actin (SMA; a 
marker of myofibroblasts) and podoplanin. Under nor-
mal conditions, podoplanin is expressed by lymphatic 
endothelial cells and mesothelial cells in the peritone-
um. We demonstrated that 15 of 18 biopsies from pa-
tients with EPS demonstrated a diffuse accumulation of 
podoplanin-positive cells  [3] , whereas these cells were 
focally present in 3 of 16 specimens from PD patients 
without signs of EPS, and in none of the 35 controls  [3] . 
Podoplanin-positive cells appear in four morphological 
patterns  [4] . An organized pattern was found in 8 of 24 
biopsies, with longitudinal layers of podoplanin-posi-
tive cells, a diffuse pattern (in 7 of 24 biopsies) with a 
random and at times dense podoplanin-positive cell ac-
cumulation, and a combination of those two patterns 
(‘mixed’ in 5 of 24 biopsies)  [4] . As in the previous study, 
in biopsies of some patients, an accumulation of podo-
planin-positive myofibroblasts was not present, but 
only expression by lymphatic endothelial cells (4 of 24 
biopsies, podoplanin ‘low’)  [4] . The diffuse and mixed 
patterns were associated with higher C-reactive protein 
levels (as a marker of systemic inflammation) and a 
shorter time between onset of symptoms and EPS diag-
nosis  [4] .
 Platelet-derived growth factors (PDGFs) and their re-
ceptors (PDGFRs) play pivotal roles in driving fibroblast 
and vascular smooth muscle cell proliferation, as well as 
production of extracellular matrix  [5] . The two PDGF re-
ceptor chains (PDGFRα and PDGFRβ) form homodi-
mers and heterodimers. The receptors containing the 
β-chains (PDGFRαβ and PDGFRββ) bind the ligands 
PDGF AB or BB, and PDGF BB or DD, respectively  [5, 6] .
 Pericytes are mesenchymal-derived cells which have 
been described to be a major source for fibroblasts in re-
nal injury models  [7, 8] as well as in other organs  [9] . 
Within the renal tubulointerstitium, the majority of 
SMA-positive cells were derived from pericytes, which 
expressed PDGFRβ  [10] . Several previous studies used 
PDGFRβ to describe the distribution of pericytes, and 
therefore it is an accepted marker of pericytes  [11–13] . 
The corresponding ligand PDGF B is an important dif-
ferentiation factor for pericytes  [14] . As the source of 
myofibroblasts in the peritoneal cavity is still poorly de-
scribed, this study aimed to further characterize the ex-
pression of the PDGFRβ in the human peritoneum and 
by doing so to elucidate pericytes as a potential source of 
podoplanin-positive myofibroblasts.
 Materials and Methods 
 In this retrospective analysis, we included peritoneal biopsies 
from patients with EPS (n = 6) and patients on PD without signs 
of EPS (n = 5), and compared them with normal peritoneum (n = 
3) and peritoneum from uremic patients (n = 5). Consecutive sec-
tions were stained for PDGFRβ (Y92, EPITOMICS, Burlingame, 
Calif., USA), SMA (1A4, DakoCytomation, Glostrup, Denmark), 
and podoplanin (D2–40, Signet Laboratories, Dedham, Mass., 
USA) as previously described in detail  [3, 4] .  Slides were scored 
semiquantitatively by 2 observers blinded to the diagnosis. The 
interobserver variability of the scores reflected by weighted κ were 
0.61 for PDGFRβ, 0.68 for podoplanin and 0.56 for SMA. Illus-
trated were the mean of the two scores ± SEM.
 The tissue sections were obtained from the peritoneal biopsy 
registry at the Robert-Bosch-Hospital, Stuttgart, Germany. The 
collection of human peritoneal tissue, blood and peritoneal dialy-
sate for research purposes was approved by the local ethics com-
mittee (#322/2009BO1, Eberhard-Karls University Tübingen, 
Germany). All patients had given their written informed consent 
concerning a scientific workup of tissues taken during surgery.
 Biopsies from the peritoneum from EPS patients were obtained 
during peritonectomy and enterolysis. These were formalin-fixed 
and paraffin-embedded following routine protocols. The clinical 
information is illustrated in  table 1 . For the diagnosis of EPS, the 
clinical criteria described by Nakamoto  [15] , radiological criteria 
by Vlijm et al.  [16] and histological criteria by Honda et al.  [17] 
were applied. The morphological features of podoplanin staining 
were used as previously described  [4] .
 Statistics 
 The nonparametric Kruskal-Wallis was performed with Dunn’s 
multiple comparison (posttest) for the comparison of immunohisto-
chemistry scores using Graph Pad Prism 5 for Windows (version 
5.03). A p < 0.05 was considered statistically significant. Illustrated in 
the scatterplots are mean ± SEM. The interobserver variability was 
illustrated by calculating weighted κ (using Graphpad Quickcalcs on-
line software at http://graphpad.com/quickcalcs/kappa1.cfm).
 Results 
 Localization of PDGFRβ in Peritoneal Biopsies 
 The clinical information of the studied patients is sum-
marized in  table 1 . As the control groups were small, these 
were combined in the further analysis (3 biopsies with 
normal peritoneum and 5 from uremic patients). Look-
ing at the results of the uremic patients separately did not 
change the results.
 PDGFRβ was expressed by cells of arterial walls in all 
biopsies as expected ( fig. 1 a). In the biopsies with well-
preserved peritoneum, a number of PDGFRβ-positive 
cells was scattered throughout the interstitial tissue par-
ticularly in the vicinity of larger arteries. These PDGFRβ-
positive interstitial cells with the appearance of fibro-
blasts were not positive for SMA or podoplanin on con-
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secutive sections. SMA was almost exclusively restricted 
to arterial walls. Therefore, a population of scattered 
PDGFRβ-positive cells with fibroblastic appearance was 
found to be SMA negative. In the control biopsies, podo-
planin was restricted to mesothelial cells and lymphatic 
vessels. The semiquantitative scores for PDGFRβ-positive 
cells were higher than for SMA-positive cells in normal 
peritoneum (due to the described population;  fig. 2 ).
 In the 5 biopsies from patients on PD without EPS, a 
prominent accumulation of PDGFRβ-positive cells was 
present particularly in the submesothelial fibrotic area 
( fig. 1 d–f). An overlapping pattern was seen in these fibrot-
ic areas for SMA. Still, the number of PDGFRβ-positive 
cells outnumbered the SMA-positive cells in many areas 
( fig. 1 d, f). This indicates that at least two populations of 
PDGFRβ are present in the injured peritoneum (the dou-
ble-positive cells reflect myofibroblasts). Importantly there 
was also a strong and diffuse accumulation of SMA and 
PDGFRβ-positive cells; no podoplanin staining was present 
on consecutive sections ( fig. 1 e). Therefore, myofibroblasts 
in simple fibrosis related to PD do not express podoplanin.
 Five of the 6 biopsies from patients with EPS demon-
strated a diffuse accumulation of podoplanin-positive 
cells ( fig. 1 g–i). Both the PDGFRβ and the SMA staining 
demonstrated a very similar pattern. Therefore, in EPS a 
third population of cells was present expressing all three 
markers. In EPS, the three markers labelled the same fi-
broblastic cells, but differed in the labelling of vessel walls 
and lymphatic vessels (as expected). A significant in-
crease in the PDGFRβ, SMA, and podoplanin scores was 
seen in EPS as compared to controls ( fig. 2 ).
 Discussion 
 Pericytes found major attention as the source for the 
extracellular matrix producing myofibroblasts  [13] . Peri-
cytes are located on the abluminal surface of small vessels, 
 Table 1.  Clinical information and laboratory values of study population (n or mean ± SD)
Variable Normal
biopsies
Uremic patients
(not on PD)
PD EPS
Patients 3 5 5 6
Female/male 2/1 3/2 4/1 5/1
Age, years 50.2 ± 13.2 54.4 ± 18.1 64.4 ± 11.8 51.3 ± 9.9
PD duration, months 24.2 ± 19.1 70.5 ± 22.3
Peritonitis rate, months 1:15 1:47 
PDF
Neutral
Acidic
ND
4
0
1
2
3
1
Icodextrin 2/5 5/6
Transporter status
High/high average
Low/low average
ND
2
1
2
4
2
Diabetes 0/3 3/5 3/5 0/6
Smoker 0/3 2/5 2/5 2/6
Hypertension 1/2 3/5 4/5 6/6
Laboratory values
Hb, g/dl (13–18) 12.9 ± 2.4 10.6 ± 1.0 12.3 ± 2.2 10.0 ± 1.8
Leukocytes, g/l (4.0–11.3) 4.8 ± 1.0 8.5 ± 1.7 6.4 ± 1.6 6.9 ± 3.2
Phosphate, mmol/l (0.68–1.68) 1.7 ± 0.3 1.3 ± 0.4 1.1 ± 0.3
Calcium, mmol/l (1.90–2.70) 2.3 ± 0.1 2.1 ± 0.1 2.2 ± 0.1 2.1 ± 0.2
PTH, pmol/l (1.1–7.3) 34.3 ± 8.3 31.1 ± 29 37.2 ± 47.1
Urea-N, mg/dl (10–25) 65.6 ± 23.5 44.6 ± 22.5 37.8 ± 15.3
Creatinine, mg/dl (0.5–1.4) 0.8 ± 0.1 5.1 ± 1.0 5.1 ± 2.6 6.9 ± 3.7
 PDF = Peritoneal dialysis fluid; Hb = hemoglobin; ND = not determined; PTH = parathyroid hormone. Fi-
gures in parentheses indicate normal ranges.
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and are embedded in part in the vascular basement mem-
brane  [13] . In several organs including the liver, kidney 
and skin in systemic sclerosis, the pericyte has been sug-
gested as a major source of myofibroblasts [reviewed in 
 13 ]. Furthermore, pericytes play a role in angiogenesis 
 [18] . The distribution of pericytes in the peritoneum from 
patients on PD has not been illustrated. Furthermore, the 
source of myofibroblasts during peritoneal injury has not 
been well defined. Postulated sources are a tissue-resident 
cell (like a pericyte), bone marrow-derived cells (fibro-
cytes), cells derived from the epithelium (epithelial-mes-
enchymal transition, EMT), as well as from endothelial 
cells  [9] . EMT has been given a lot of attention in perito-
neal fibrosis as in renal fibrosis  [2, 19] . In renal fibrosis, 
the enthusiasm for EMT as a major contributor to myo-
fibroblasts has decreased as genetic tracing experiments 
were not consistent with this mechanism  [20] . A recent 
study used cell fate mapping in models of peritoneal in-
jury. It did not find evidence for EMT but described a 
population of fibroblasts consistent with pericytes as the 
source of myofibroblasts  [21] .
 To further define the source and potential mechanism 
of peritoneal fibrosis, this retrospective analysis was per-
formed in the human peritoneum. In the normal perito-
neum, a scattered population of PDGFRβ-positive cells 
with fibroblastic appearance was present which did not 
express SMA. In patients on PD, a high number of 
PDGFRβ-positive cells were present. On consecutive sec-
tions, a larger population of these cells colocalized with 
SMA-positive cells and therefore reflects myofibroblasts. 
These cells did not express podoplanin. In EPS, the podo-
planin-positive cell population demonstrated an overlap-
ping pattern for both SMA and PDGFRβ. Therefore, this 
is the first study which illustrates three different popula-
tions of cells with fibroblastic appearance in the human 
peritoneum. The scattered PDGFRβ-positive cells (which 
neither express podoplanin nor SMA) in the normal peri-
toneum most likely reflect pericytes. Two populations of 
myofibroblasts are present in peritoneal fibrosis and EPS. 
These can be separated by the expression of podoplanin. 
All three markers come together in EPS. The expression 
of PDGFRβ suggests that the myofibroblasts in perito-
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 Fig. 1. Illustration of PDGFRβ in peritoneal biopsies. Immunohis-
tochemistry was performed on consecutive tissue sections from 
peritoneal biopsies of patients not on PD ( a–c ), on PD without 
signs of EPS ( d–f ) and on PD with signs of EPS ( g–i ) for PDGFRβ 
( a ,  d ,  g ), podoplanin ( b ,  e ,  h ), and smooth muscle actin (SMA;  c , 
 f ,  i ). In normal peritoneal biopsies, PDGFRβ was found to be ex-
pressed in the vessel walls of larger and smaller arteries (as expect-
ed for pericytes; arrowhead in  a ); additionally, a prominent popu-
lation of interstitial cells with fibroblastic appearance was positive 
(arrow in  a ). Podoplanin was expressed by mesothelial cells (ar-
rowhead in  b ) and SMA in smooth muscle cells of arteries and 
arterioles (arrowhead in  c ). A prominent consecutive accumula-
tion of PDGFRβ-positive cells and SMA-positive cells was present 
in the submesothelial fibrotic zone in the patient on PD (arrow-
head in  d and  f ). In contrast, PDGFRβ-positive cells outnumbered 
the SMA-positive cells in some areas (arrow in  d and  f ). The podo-
planin staining demonstrates only scattered lymphatic vessels (ar-
rowhead in  e ). In EPS, the podoplanin-positive cell population (ar-
row in  g – i ) demonstrated expression of all three markers, whereas 
no overlap was seen in the vascular cells (arrowhead in  g–i ). 
 Fig. 2. Illustration of the expression of PDGFRβ, SMA and podoplanin in peritoneal biopsies. Mean semiquantitative scores are illus-
trated as scatter plots.  *  p < 0.05;  * *  p < 0.01;  * * *  p < 0.001. 
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neal injury are related to pericytes. These data are consis-
tent with a recent study which demonstrated that the ma-
jority of myofibroblasts in mice after peritoneal injury 
come from a local population of fibroblasts  [21] . Further-
more, these cells expressed PDGFRβ  [21] .
 PDGFRβ might not only be a marker, but also a func-
tional player in both peritoneal fibrosis and EPS. This re-
ceptor binds PDGF AB, PDGF BB or DD (depending on 
the second PDGFR chain).
 In vitro, it has been demonstrated that PDGF-AB re-
sulted in a time- and dose-dependent proliferation of hu-
man peritoneal fibroblasts  [22] . Peritoneal dialysate from 
patients with peritonitis induced proliferation of these 
cells, which could be partially inhibited by an anti-PDGF 
antibody  [22] . Overexpression of PDGF-B in the perito-
neum resulted in angiogenesis, increased collagen gene 
expression, but only transient fibrogenesis  [23, 24] . Ima-
tinib mesylate is a tyrosine kinase inhibitor which inhibits 
PDGFR signaling and is increasingly used for fibrotic dis-
eases like systemic sclerosis  [25] , nephrogenic systemic 
fibrosis  [26] and others. Imatinib has been used in the 
model of chlorhexidine-induced peritoneal injury in rats 
without a significant effect on peritoneal fibrosis  [27] . In 
contrast, in a model of hypochlorite-induced peritoneal 
injury, imatinib reduced fibrosis  [21] . An important piece 
of information from the study is that the podoplanin-pos-
itive myofibroblasts in EPS also express PDGFRβ. Ascites 
from patients with EPS contained elevated levels of 
PDGF-AB and induced proliferation of fibroblasts in vi-
tro  [28] . Furthermore, proliferation of fibroblasts was 
partially blocked by a tyrosine kinase inhibitor  [28] . This 
not only implies pericytes as a potential source of this cell 
population, and PDGF-B as a potential pathogenic factor, 
but it also provides a therapeutic target. 
 This retrospective analysis has shortcomings. Most 
importantly, only a small number of biopsies was includ-
ed in this analysis. Unfortunately, we have no informa-
tion on the levels of PDGF AB, BB or DD in the dialysate 
of these patients. Finally, a general problem is that there 
is no single marker for pericytes. Therefore, pericytes 
need to be defined by the combination of ultrastructural 
analysis and two or more markers of pericytes [e.g. 
PDGFRβ, chondroitin sulfate proteoglycan 4 (NG2), 
SMA, etc]. Multicolor fluorescence will help in future 
studies to further define these cells in the peritoneum. 
Due to restrictions of materials and antibodies which 
work on archival tissue, we were limited to consecutive 
sections in the current study.
 We suggest that PDGFRβ-positive cells might play an 
important role in human peritoneal injury, and therefore 
the pathogenetic role of these cells (pericytes as a source 
of fibroblasts) and targeting these cells need to be further 
evaluated.
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